Crossmark

Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study

Crossref DOI link: https://doi.org/10.1016/j.abd.2021.11.002

Published Print: 2022-09

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Oguz Topal, Ilteris http://orcid.org/0000-0001-8735-9806
Baysak, Sevim http://orcid.org/0000-0001-9666-5821
Altunay, İlknur Kıvanç http://orcid.org/0000-0002-1354-7123
Kara Polat, Asude http://orcid.org/0000-0002-5040-6901
Arıkan, Eylem Emel http://orcid.org/0000-0002-4289-0166
Özkur, Ezgi http://orcid.org/0000-0002-9136-7021
Aytekin, Sema http://orcid.org/0000-0003-1376-1573
Dogan, Bilal http://orcid.org/0000-0002-0855-5209
Özkök Akbulut, Tuğba http://orcid.org/0000-0001-9995-2543
Topaloğlu Demir, Filiz http://orcid.org/0000-0002-2049-1316
Karadağ, Ayşe Serap http://orcid.org/0000-0003-4333-8274
License Information

Text and Data Mining valid from 2022-09-01

Version of Record valid from 2022-06-22
More Information

This article is maintained by: Elsevier

Article Title: Evaluation of the efficacy, safety, and side effects of secukinumab in patients with moderate-to-severe psoriasis: real-world data from a retrospective multicenter study

Journal Title: Anais Brasileiros de Dermatologia

CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.abd.2021.11.002

Content Type: article

Copyright: © 2022 Published by Elsevier España, S.L.U. on behalf of Sociedade Brasileira de Dermatologia.

Document is current

Any future updates will be listed below